News

Latest news

Hide mandatory notifications of trade

BIONOR PHARMA ASA – SUCCESSFUL COMPLETION OF SUBSEQUENT OFFERING

(Oslo, 23 October 2013) Reference is made to the prospectus dated 7 October 2013 and the stock exchange announcement dated 8 October 2013 concerning the subsequent offering (the "Subsequent Offering") of up to 7,500,000 shares (the "Offer Shares") in Bionor Pharma ASA (the "Company") at a subscription price of NOK 2.75 per share. The Company reports that the Subsequent Offering was oversubscribed.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES

The subscription period in the Subsequent Offering ended on 22 October 2013 at 16.30 (CET). As a result of the Subsequent Offering, the Company will issue 7,500,000 Offer Shares at NOK 2.75 per share raising gross proceeds of approximately NOK 20.6 million.

All subscribers being allotted Offer Shares will receive a letter confirming the number of Offer Shares allotted to the subscriber and the corresponding amount to be paid. This letter is expected to be distributed on or about today's date.

Payment for the Offer Shares will fall due on 28 October 2013 and delivery will take place on or about 8 November 2013. Following registration of the issue of the Offer Shares the total number of issued shares in the Company will increase by 7,500,000 shares, from 218,326,348 shares to 225,826,348 shares. The new share capital after the registration of the share capital increase will be NOK 56,456,587.

The Offer Shares may not be transferred or traded before they are fully paid and the share capital increase pertaining to the Subsequent Offering has been registered with the Norwegian Register of Business Enterprises. It is expected that the share capital increase will be registered in the Norwegian Register of Business Enterprises on or about 7 November 2013 and that the Offer Shares will be admitted to trading on Oslo Børs 8 November 2013.

SEB is acting as sole manager for the Subsequent Offering.

For further information, please contact:
Anker Lundemose, CEO Bionor Pharma, +47 23 01 09 60
Synne H Røine, CFO Bionor Pharma, +47 99 22 98 92


About Bionor Pharma:
Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange (OSE:BIONOR), and is developing vaccines for viral infections such as HIV and Influenza. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases.

More information about Bionor Pharma is available at www.bionorpharma.com

This publication is not for distribution, directly or indirectly, in or into the United States, nor is it an offer for sale of or the solicitation of an offer to purchase securities in the United States. Any securities referred to herein have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration or pursuant to an exemption from registration under the U.S. Securities Act. Copies of this publication are not being, and may not be, distributed or sent into the United States.

This information is subject of the disclosure requirements acc. to §5-12 (Norwegian Securities Trading Act)